Company intelligence / Profile preview

Essentialis, Inc.

Carlsbad, California, United Statesorpha.net ↗

Ownership: Private
Development stage: Phase 2

Overview

Essentialis developed DCCR (diazoxide choline controlled-release), a once-daily oral tablet that entered Phase II/III development for the treatment of Prader-Willi Syndrome in 2017. The company had several discontinued programs including treatments for Hypertriglyceridemia, Staphylococcal Infections, and Gram-Positive Bacterial Infections.

Therapeutic areas: Rare DiseasesMetabolic DisordersInfectious Diseases
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

diazoxide choline

Phase 2

Indications: Prader-Willi syndrome

Beyond the preview

Go deeper on Essentialis, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Essentialis, Inc..

Explore the full profile